Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Next Previous
Trial Profile

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanidatamab zovodotin (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Biliary cancer; Bladder cancer; Cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Gynaecological cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Zymeworks

Most Recent Events

  • 29 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 07 Dec 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2025.
  • 15 Oct 2023 According to Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023, based on these results, 2.5 mg/kg Q3W regimen was chosen as the RD.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top